Regeneron Beats Q2 Estimates on 38% Dupixent Sales Jump to $6 Billion
Regeneron reported second-quarter revenue of $4.3 billion, beating the $3.82 billion estimate, as adjusted earnings per share of $14.29 topped forecasts.
Global sales of the skin and asthma drug Dupixent surged 38% to a record $6 billion, a figure recorded by partner Sanofi, while U.S. EYLEA HD sales rose 52% to $596 million. The company raised its full-year non-GAAP gross margin outlook to 84%-85% and lowered capital expenditure guidance, following the complete repayment of a development balance owed to Sanofi.
From the sources (3 posts)
@businessSanofi reported better-than-expected profit growth and nudged its guidance higher, helped by surging demand for its top-selling skin and asthma medicine Dupixent
@wallstengineREGENERON $REGN Q2’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $4.3B (Est. $3.82B) 🟢; +17% YoY 🔹 Adj. EPS: $14.29 (Est. $10.26) 🟢; +11% YoY 🔹 Dupixent Global Net Sales: $6.0B; +38% YoY 🔹 EYLEA HD U.S. Net Sales: $596M; +52% YoY FY26 Guide: 🔹 Non-GA
@alphasenseinc$REGN Earnings: - Second quarter 2026 revenues increased 17% to $4.3 billion versus second quarter 2025 - GAAP EPS of $12.23, including $1.02 negative impact from IPR&D; non-GAAP EPS of $14.29, including $0.99 negative impact from IPR&D -